Cogent Biosciences (COGT) Non-Current Assets (2017 - 2026)

Cogent Biosciences' Non-Current Assets history runs 10 years deep, the most recent figure standing at $25.2 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 18.47% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $111.0 million (down 32.67% YoY), while the FY2025 annual figure was $27.3 million, down 13.28% from the prior year.
• Non-Current Assets was $25.2 million for Q1 2026 at Cogent Biosciences, down from $27.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $69.5 million in Q3 2023 to a low of $12.1 million in Q1 2022.
• Historically, Non-Current Assets has averaged $37.4 million across 5 years, with a median of $35.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 393.68% in 2022, then plunged 50.29% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $35.8 million in 2022, then climbed by 19.03% to $42.7 million in 2023, then dropped by 26.34% to $31.4 million in 2024, then decreased by 13.28% to $27.3 million in 2025, then slipped by 7.52% to $25.2 million in 2026.
• The last three Non-Current Assets figures came in at $25.2 million (Q1 2026), $27.3 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.